PHARMADRUG™

AN INTEGRATED PHARMACEUTICAL COMPANY FOCUSED ON NATURAL BASED MEDICINES

THC| CBD| CEPHARANTHINE |DMT| PSILOCYBIN

Corporate Overview

CSE: PHRX **OTC:** LMLLF

September 2021

Disclaimer

Confidentiality and Disclaimer

The information contained in this presentation is confidential and shall be kept in strict confidence by you. You hereby agree that by accepting a copy of this presentation you will be deemed to have agreed to keep all information in this presentation strictly confidential and not to disclose, reproduce or transmit such information for any purpose whatsoever. Each person accepting this presentation hereby agrees to return it, along with any copies, promptly upon request. This presentation of Aura Health Inc. ("Aura" or the "Company") is for information only and shall not constitute an offer to buy, sell, issue or subscribe for, or the solicitation of an offer to buy, sell or issue, or subscribe for any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The information contained herein is subject to change without notice and is based on publicly available information, internally developed data and other sources. Where any opinion or belief is expressed in this presentation, it is based on the assumptions and limitations mentioned herein and is an expression of present opinion or belief only. This presentation should not be construed as legal, financial or tax advice to any individual, as each individual's circumstances are different. Readers should consult with their own professional advisors regarding their particular circumstances. The Company makes no representation or warranty, express or implied, as to the accuracy or completeness of any information (whether communicated in written or oral form), other than this presentation, regarding the Company or its affiliates transmitted or made available to you. The Company expressly disclaims any and all liability relating to, or resulting from, the use of such other information which may be provided to you. Prospective investors are encouraged to conduct their own analysis and reviews of the company and of the information contained in this presentation and to carefully review and consider the various disclosures made by the Company in its reports filed on SEDAR (www.sedar.com). None of the Company's securities have been registered with or approved or disapproved by any Canadian provincial securities commission, by the U.S. Securities and Exchange Commission or by any state or foreign securities commission nor has any Canadian provincial securities commission, the U.S. Securities and Exchange Commission or any state or foreign securities commission reviewed or passed upon the accuracy or adequacy of this presentation. No independent person has confirmed the accuracy or truthfulness of the information contained in this presentation, nor whether it is complete. Any representation to the contrary is illegal. The securities being offered have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws. Any securities offered will be offered only to "accredited investors", as such term is defined under Regulation D and Regulation S under the U.S. Securities Act, respectively, and to persons in Canada who are "accredited investors" as defined under National Instrument 45-106 - Prospectus Exemptions on a private placement basis only. The information in this document is not targeted at the residents of any particular country or jurisdiction and is not intended for distribution to, or use by, any person in any jurisdiction or country where such distribution or use would be contrary to local law or regulation.

Cautionary Statement Regarding Forward-Looking Information and Risk Factors

This presentation includes forward-looking information and forward-looking statements and information (collectively, "forward-looking information") within the meaning of applicable Canadian and U.S. securities laws. Statements containing the words "believe", "expect", "intend", "should", "seek", "anticipate", "will", "positioned", "project", "risk", "plan", "may", "estimate" or, in each case, their negative and words of similar meaning are intended to identify forward-looking information. Forward-looking information is based on currently available competitive, financial, and economic data and operating plans as of the date of this presentation, but are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements or industry results to be materially different from those expressed or implied by such forward-looking information. Such factors are based on information currently available to the Company, including information obtained from third party industry analysts and other third party sources, and are based on management's current expectations regarding future growth, results of operations, future capital (including the amount, nature and sources of funding thereof) and expenditures, the Company's anticipated business strategies, anticipated trends in the Company's business and anticipated market share and legalization in the cannabis industry. The Company can give no assurance that these estimates, expectations and projections will prove to have been correct. The forward-looking information contained in this presentation is expressly qualified by this cautionary statement. A number of risks, uncertainties and other factors could cause actual results to differ materially from the results discussed in the forward-looking information, including, but not limited to, the following: general industry and market conditions and growth rates; legislative and regulatory developments; general economic conditions and levels of economic activity including interest rate fluctuation; the Company has limited operating history in an emerging area of business and had negative cash flows from operations in its most recently completed financial year; adverse events relating to the Company's products could result in risks relating to product liability or other legal claims; risks related with reliance on key personnel; the Company's senior management has been key to its growth and the Company may be adversely affected if it is unable to retain them; conflicts of interest develop or the Company loses any key member of its senior management team; changes in employee relations; ability to enforce non-competition and other restrictive covenants in the Company's agreements; risks associated with implementation of growth initiatives; financing risks; lower than expected future revenues and profitability; the Company may face intense competition and expects competition to increase in the future, which could inhibit its development of customer base and generating revenue; the Company's ability to establish, maintain and defend intellectual property rights; changes to public perception of cannabis use; factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking information; general business, economic and competitive uncertainties; regulatory risks including risks related to the granting and expected timing of the approval of licenses and permits; ability to comply and the cost of compliance with changing regulations; risks related to criminal or civil sanctions in connection with failure to comply with regulations; risks associated with acquisitions and expansion; risks inherent in manufacturing operations; and other general risks of the cannabis industry as well as those risk factors disclosed elsewhere below. Such statements are based upon the current beliefs and expectations of the Company's management and are subject to significant business, social, economic, political, regulatory, competitive and other risks, uncertainties, contingencies and other factors. Many assumptions are based on factors and events that are not within the control of the Company. Actual future results may differ materially from historical results or current expectations. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. In addition, even if the outcome and financial effects of the plans and events described herein are consistent with the forward-looking information contained in this presentation, those results or developments may not be indicative of results or developments in subsequent periods. Although the Company has attempted to identify important risks and factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors and risks that cause actions, events or results not to be as anticipated, estimated or intended. You should not place undue reliance on forward-looking information, which is based on the information available as of the date of this presentation. Forward-looking information contained in this presentation is as of the date of this presentation and, except as required by applicable law, the Company assumes no obligation to update or revise them to reflect new events or circumstances. Historical statements should not be taken as a representation that such trends will be replicated in the future. No statement in this presentation is intended to be nor may be construed as a profit forecast. To the extent any forward-looking information in this presentation constitutes "future- oriented financial information" or "financial outlooks" within the meaning of applicable Canadian securities laws, such information is being provided to demonstrate the anticipated market penetration and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such future-oriented financial information and financial outlooks. Future-oriented financial information and financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to the risks set out above under the heading "Cautionary Statement Regarding Forward-Looking Information and Risk Factors". The Company's actual financial position and results of operations may differ materially from management's current expectations and, as a result, the Company's revenue and expenses may differ materially from the revenue and expenses profiles provided in this presentation. Such information is presented for illustrative purposes only and may not be an indication of the Company's actual

PharmaDrug is a specialty pharmaceutical company focused on the **research**, **development** and **commercialization** of **controlled-substances** and **naturally-derived medicines**.

PHARMADRUG™

EU Narcotics License
with GMP Certification
CBD & THC

Controlled-substance Distributor

Sairiyo Therapeutics

Psychedelics
(DMT / Tryptamines)

COVID & Cancer
(Cepharanthine)

Biotechnology

Slim Winkel

Psychedelics Truffles

Functional Mushrooms

Medical Supplements

Our growth strategy

- **Pursue novel uses**, formulations and delivery forms of **psychedelics (DMT)** for FDA approval
- **Advance clinical development of novel Cepharanthine formulation** (Oral Anti-viral) for COVID-19 by leveraging existing safety/efficacy track record
- **Repurpose Cepharanthine to treat cancers** with high unmet medical needs
- **Expand medical cannabis distribution in EU**
- **Launch branded psychedelic and functional mushrooms products** to be sold via our **online** retail platforms
- **Enhance** Shareholder value by advancing product pipeline via FDA clinical trials, partnerships, patents, FDA designations, production control, licensing and sales



Biotechs Leading the Way

PSYCHEDELICS ⟷ **COVID-19**

COMPANY	atai LIFE SCIENCES	COMPASS Navigating Mental Health Pathways	mindmed	HARMADRUG™	CytoDyn	RELIEF THERAPEUTICS	ATEA Pharmaceuticals
COMPOUNDS	Multiple psychedelics	Psilocybin	LSD	DMT Cepharanthine	Leronlimab	RLF-100	AT-527
INDICATION	Multiple indications	Depression	Mental Illness	COVID-19 Cancer Glaucoma	COVID-19	COVID-19	COVID-19
CLINICAL	Multiple clinical phases	FDA Phase 2b clinical trial	Non-FDA Phase 2 clinical trials	FDA clinical trials in 2022	Phase 3 clinical trial	Phase 2 clinical trial	Phase 2 clinical trial
VALUATION	$2.8 Billion market cap	$1.5 Billion market cap	$1.5 Billion market cap	~$20 Million market cap	$800 Million market cap	$800 Million market cap	$2.6 Billion market cap

Pharmaceutical Pipeline
With focus on FDA approval

PRODUCT	INDICATION	PATIENTS	MARKET SIZE
Cepharanthine	COVID-19	+1 billion	+$10 billion
	Cancer #1	100 million	+$5 billion
	Cancer #2	< 200 thousand	+$1 billion
DMT	Glaucoma		

Sairiyo Therapeutics

Cepharanthine for COVID-19

- Pursuing FDA Clinical Trials for Mild to Moderate COVID-19 Cases
- The U.S. government announced a 'Whole-of-Government Effort', aimed at developing oral antiviral drugs for home use
- FDA IND-enabling pre-clinical studies and GMP manufacturing of Cepharanthine established
- Cepharanthine has been shown to significantly inhibit SARS-Cov-2 viral entry by binding to and blocking viral spike protein engagement with its human cell surface docking site, the angiotensin converting enzyme 2 (ACE2) receptor
- Several 3rd party, peer-reviewed drug screens have independently demonstrated Ceharanthine's potent anti-viral activity against Covid-19
- Sairiyo holds exclusive rights to all fields of use for a novel, high (~70%) orally bioavailable formulation of Cepharanthine
- With US patent protection until 20316, Sairiyo's is developing Cepharanthine as a potential oral medication for mild to moderate covid in a home setting

Multiple, independent studies reveal Cepharanthine's potent antiviral activity against SARS-CoV-2

iScience

CellPress
OPEN ACCESS

Article

Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment

https://pubmed.ncbi.nlm.nih.gov/33817567/

OXFORD

Briefings in Bioinformatics, 00(00), 2021, 1–9

doi: 10.1093/bib/bbaa387
Case Study

Transcriptome analysis of cepharanthine against a SARS-CoV-2-related coronavirus

https://pubmed.ncbi.nlm.nih.gov/33423067/

ACS Pharmacology & Translational Science

pubs.acs.org/ptsci

Article

Identifying SARS-CoV-2 Entry Inhibitors through Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped Particles

https://pubmed.ncbi.nlm.nih.gov/32839777/

RESEARCH ARTICLE

JOURNAL OF MEDICAL VIROLOGY WILEY

SARS-CoV-2 and SARS-CoV: Virtual screening of potential inhibitors targeting RNA-dependent RNA polymerase activity (NSP12)

https://pubmed.ncbi.nlm.nih.gov/32579254/

Cepharanthine and COVID-19
Development Timeline

PRE-IND SUBMISSION

Early September 2021

FDA MEETING DATE AWARDED

Late September 2021

RESPONSE MEETING FROM FDA WITHIN 60 DAYS

November 2021

DEPENDING ON OUTCOME OF PRE-IND MEETING:

- Additional toxicity work required; or
- Leveraging historical safety data, prepare IND to commence Phase 2a Clinical Trial for mild-moderate Covid-19.

Sairiyo Therapeutics

Cepharanthine & Cancer

Sairiyo is currently focused on advancing the clinical development of cepharanthine to treat rare forms of cancer.

- Q1 2021: Granted FDA Orphan Drug Designation for cepharanthine as a treatment for esophageal cancer
- Esophageal cancer frequently evades chemotherapy. Cepharanthine has shown to directly kill cancer cells & reduce development of chemoresistance.
- Conducting preclinical study to assess monotherapy or combined therapy with current standard of care:
  - Study 1: 60 cell lines - Cepharanthine vs Chemo
  - Study 2: 20 cell lines - Cepharanthine in combination with Chemo
  - Study 3: Gold standard animal model to evaluate Cepharanthine + Chemo synergy in 3 high-medical need malignancies

Cepharanthine and Cancer
Development Timeline

Pre-clinical study #1 has shown positive results for **Esophageal, Liver, Skin and Colorectal**

Results of **Cepharanthine** + chemo study #2

Late September 2021

Confirmatory **animal studies initiated**

November 2021

Prepare **pre-IND submission**

Q1 2022

DMT OVERVIEW: Harnessing the power of DMT to treat non neuro-psychiatric conditions

STRATEGIC APPROACH: HOLY TRINITY FOR PSYCHEDELIC COMMERCIAL STRATEGY:

- Unique indication
- Unique formulation
- Unique delivery technology

Partnered with **the University of Michigan** to study the role of endogenous DMT in the brain

Obtained orphan drug designation for DMT to treat ischemia-reperfusion injury in **organ transplant patients**

Sponsored research agreement with the **Terasaki Institute** to develop a **novel ocular drug delivery for DMT in eye diseases**

DMT in the eye

Based on compelling 3rd party data examining the impact of serotonin signalling in the eye, PharmaDrug is pursuing an R&D strategy for DMT to treat glaucoma

- Glaucoma causes pathological increases in intraocular pressure ("IOP") leading to vision loss
- Existing treatments (typically eye drops) are only partially successful due side effects, poor compliance, and the increase in IOP overnight
- Research has shown that elevated IOP can be reduced though activation of specific serotonin receptors
- Tryptamine family members (of which DMT is one) have been shown to reduce IOP by activating 5HT-1a and 5HT-2a receptors
- PharmaDrug is currently evaluating & developing novel formulations of DMT to address elevated IOP
- Partnered with Terasaki Institute to develop a proprietary ocular delivery technology for DMT

Controlled-substance division

COMMERCIAL DISTRIBUTION MEDICAL CANNABIS AND CONTROLLED-SUBSTANCES IN EU

- 100% ownership in a Licensed Schedule 1 Narcotics Distributor (EU GMP)
- Permit to import and distribute medical cannabis in Germany and the EU
- EU GMP certification enabling in-house and white label production
- Currently selling medical cannabis to over 300 pharmacies in Germany
- German cannabis market projected to reach €7.7 billion by 2028[1]
- Plans to expand medical cannabis and pharmaceutical psychedelics in EU

Sources:
[1]https://www.forbes.com/sites/dariosabaghi/2021/08/09/how-big-is-germanys-medical-cannabis-market/?sh=6543c3c540f4

Pharmadrug production: bringing in-demand products to market

Pharmadrug Production distributes **Bedrocan Cannabis** from the Netherlands to over **300 pharmacies** in Germany

Rapid market evolution towards oil-based products underway
Oil segment share - 80%

Launching sales of in-house branded synthetic and full spectrum **THC oils** in Q4 2021

Plans to distribute **pharmaceutical psychedelics** as they become legal

SUPER SMART

Retail Psychedelics Overview

Super Smart is building a vertically integrated retail business with a goal to elevate the use of psilocybin and functional mushrooms as natural based medicines and supplements

Slim Winkel

- Under the **Slim Winkel** brand, the company is building e-commerce platforms in the US and in Europe
- **Developing and introducing in-house branded products** with a focus on scientifically-backed formulations and full consumer transparency
- **Slim Winkel U.S.** – Branded, functional mushrooms products to act as a beachhead for psychedelics once adult-use is legalized
- **Slim Winkel Netherlands** – currently selling Psilocybin and Functional Mushrooms in the Netherlands. Functional Mushrooms online across Europe

Super smart: in-house branded products

Slim's MycoWe℞ is a line of premium functional mushroom products for sale in the United States and eventually in Europe

- **Production of Slim's own functional mushroom** blend now completed with sales expected at the beginning of October.
- **Initial suite of products** will be called MycoWe℞ and the first release will serve as a once per day complete 6 functional mushroom dose in one pill
- **High potency preparations** using advanced extraction processes to provide the consumer with a 1 capsule/day solution
- **Product line** will only use fruiting bodies cultivated from a mushroom's natural substrate ensuring maximum potency in every capsule
- **Brand focus** will be on transparency, premium quality standards and rigorous research

Intellectual Property

PATENTS



US010576077B2

(12) **United States Patent**
Bauta et al.

(10) **Patent No.: US 10,576,077 B2**
(45) **Date of Patent: Mar. 3, 2020**

(54) **PHARMACEUTICAL SALT FORMS OF CEPHARANTHINE AND TETRANDRINE**

(71) Applicant: **Southwest Research Institute**, San Antonio, TX (US)

(72) Inventors: **William E. Bauta**, San Antonio, TX (US); **Joseph A. McDonough**, Helotes, TX (US); **Hong Dixon**, Helotes, TX (US); **Stephen T. Wellinghoff**, San Antonio, TX (US); **Kevin Fitzpatrick**, San Antonio, TX (US)

(73) Assignee: **Southwest Research Institute**, San Antonio, TX (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **15/925,551**

(22) Filed: **Mar. 19, 2018**

(65) **Prior Publication Data**

US 2018/0303823 A1 Oct. 25, 2018

Related U.S. Application Data

(63) Continuation-in-part of application No. 15/078,782, filed on Mar. 23, 2016, now abandoned.

(60) Provisional application No. 62/136,851, filed on Mar. 23, 2015.

(51) **Int. Cl.**
A61K 31/4745 (2006.01)
A61K 9/16 (2006.01)
C07D 491/22 (2006.01)

(52) **U.S. Cl.**
CPC ***A61K 31/4745*** (2013.01); ***A61K 9/1635*** (2013.01); ***C07D 491/22*** (2013.01); *A61K 9/1682* (2013.01)

(58) **Field of Classification Search**
CPC A61K 31/4745; A61K 31/47
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,248,241	A *	7/1941	Kondo	C07D 491/18 546/31
4,816,462	A	3/1989	Nowicky	
5,534,523	A	7/1996	Ono et al.	
6,123,943	A	9/2000	Baba et al.	
6,562,837	B1	5/2003	Yim-Choi et al.	
8,067,401	B2	11/2011	Chepkwony et al.	
8,475,804	B2	7/2013	Johansen et al.	
8,889,743	B2	11/2014	Davey et al.	
9,517,234	B2	12/2016	Carroll	
9,518,022	B2	12/2016	Anuegbu et al.	
2011/0028564	A1	2/2011	Johansen et al.	
2011/0152344	A1	6/2011	Davey et al.	
2014/0073591	A1	3/2014	Gudeman et al.	
2014/0275137	A1	9/2014	Carroll	
2016/0280716	A1	9/2016	Bauta et al.	
2017/0368051	A1	12/2017	Anuegbu et al.	

FOREIGN PATENT DOCUMENTS

CN	102477041 A *	5/2012	
CN	102477041 A	5/2012	
EP	0 476 391 A2	3/1992	
EP	0476391 A2 *	3/1992	A61K 31/47
EP	1 124 554 A2	9/2003	
JP	2000080039 A	3/2000	
KR	10 0352425 B1	9/2002	
WO	2014149848 A1	9/2014	

OTHER PUBLICATIONS

Vippagunta et al (Crystalline Solids: Advanced Drug Delivery Reviews vol. 48 pp. 3-26 published 2001 (Year: 2001).*
Speakman Basics of X-Ray Powder Diffraction X-Ray training materials at MIT. Accessed Mar. 18, 2014 (Year: 2014).*
Brittain et al. "Polymorphism in Pharmaceutical Dosage Forms." Polymorphism in Pharmaceutical Solids XX (Jan. 1999) pp. 235-238 (Year: 1999).*
U.S. Office Action dated Sep. 14, 2018; issued in related U.S. Appl. No. 15/916,596 (8 pgs).
Ashtikar, et al. "Transdermal Delivery from Liposomal Formulations—Evolution of the Technology Over the Last Three Decades" , Science Direct; Journal of Controlled Release, vol. 242, pp. 126-140; published online Sep. 10, 2016.
Bhattacharya, et al. "Polymorphism in Pharmaceutical Solids, Second Edition"; Chapt. 9 "Thermoanalytical and Crystallographic Methods" (Jan. 1999), Informa Healthcare USA, RightsLinkpp. 318-346 downloaded by USPTO on Oct. 20, 2014.
Chen, et al., "The Alkaloids of Han-Fang-Chi"; from the Lilly Research Laboratories, received for publication Mar. 7, 1935, pp. 681-685.
Goho; "Tricky Business—The Crystal Form of a Drug Can be the Secret to its Success"; Science News Online; week of Aug. 21, 2004; vol. 166, No. 8; (8 pgs) <<http://www.sciencenews.org/scripts/printthis.asp?clip-%2Farticles%2F20040821%2Fclip>> accessed Feb. 28, 2005.
Hussan, et al; "A Review on Recent Advances of Enteric Coating"; IOSR Journal of Pharmacy, vol. 2, Issue 6, Nov.-Dec. 2012; pp. 5-11.
Imubushi, et al; "Total Syntheses of Optically Active Natural Isotetrandrine, Phaeanthine and Tetrandrine", Tetrahedron Letters No. 30, pp. 3399, 1968 Pergamon Press; Great Britain.
(Continued)

Primary Examiner — Timothy P Thomas
Assistant Examiner — George W Kosturko
(74) *Attorney, Agent, or Firm* — Grossman, Tucker, Perreault & Pfleger, PLLC

(57) **ABSTRACT**

The present disclosure relates to the preparation of polymorphic mixtures of Cepharanthine.2HCl. Mixtures of at least two polymorphic forms can be formed into a mobile liquid phase in organic/aqueous solvent mixtures along with enteric polymer that can be spray dried to produce solid particulate enteric formulations for medicinal drug-treatment applications.

6 Claims, 27 Drawing Sheets
(7 of 27 Drawing Sheet(s) Filed in Color)

MARKET EXCLUSIVITY

FDA Orphan Drug Designation

Cepharanthine to treat Esophageal Cancer

DMT to treat ischemia-reperfusion injury in organ transplation

OUR IP STRATEGY:

- Use patents for cepharanthine in cancers
- FDA ODD for cepharanthine in cancers
- Use patents for cepharanthine in infectious diseases
- Develop IP for ocular drug delivery and novel tryptamine formulations

Exclusive rights to the patent, method of manufacturing, clinical supply, pre-clinical data and know-how to support FDA clinical trials and approval

Milestones 2021-2022

- **Cancer** — Granted FDA Orphan Drug Designation for cepharanthine to treat esophageal cancer
- **DMT** — Granted FDA Orphan Drug Designation for DMT to treat ischemia-reperfusion injury in organ transplantation
- **Cancer** — Pre-clinical study #1 shown positive results for Esophageal, Liver, Skin and Colorectal with Cepharanthine
- **COVID-19** — FDA Pre-IND submission for Cepharanthine (early September 2021)
- **COVID-19** — FDA response to Pre-IND submission (November 2021)
- **Medical Cannabis** — Launch sales of in-house branded synthetic and full spectrum THC oils in (Q4 2021)
- **Cancer** — FDA IND-enabling results for Cepharanthine + chemo (Sept/Oct 2021)
- **Cancer** — Initiate confirmatory FDA IND-enabling animal studies (November 2021)
- **Cancer** — FDA pre-IND submission (Q1- 2022)
- **DMT** — FDA IND acceptance for Phase 2 study with John Hopkins Hospital (Q2-2022)
- **DMT** — Terasaki complete in vitro benchmarking studies of DMT and novel tryptamine for glaucoma (Q1-2022)

Relationships are key to our success

SwRI
SOUTHWEST RESEARCH INSTITUTE

Cepharanthine
GMP Manufacturer / Licensor

JOHNS HOPKINS
Center for Psychedelic & Consciousness Research

DMT
Clinical Studies

UNIVERSITY OF MICHIGAN

Endogenous DMT
Foundational Science

CrownBio

Cepharanthine
Oncology CRO

TERASAKI INSTITUTE
FOR BIOMEDICAL INNOVATION

DMT Delivery Technology
Elevated IOP-Glaucoma

Management Team

DANIEL COHEN, CFA
CEO

Daniel has over 20 years of capital markets experience, most recently spending several years as Head of Sales at Beacon Securities. During this time, Daniel successfully financed and launched multiple public companies.

PAUL VAN SLYKE, PHD
Chief Science Officer

Paul previously served as CSO of Sairiyo Therapeutics and is an entrepreneur-scientist with 18 granted and filed patents. Paul is also the co-founder and former CSO of Vasomune, a clinical stage Canadian biotech company.

KEITH LI, CPA
CFO

Keith has over 10 years of experience in public accounting andaccounting in the private sector. His specialties include audit and assurance, corporate accounting, financial reporting, and regulatory compliance services.

HARRY RESIN
President, Super Smart

Harry has worked in the cannabis industry for the last 17years as a supply chain consultant to coffee-shops in Amsterdam and as a founding member of an original Amsterdam seed company. He has also served as a staff writer for High Times.

Advisory Board

DR. YELENA Y. JANJIGIAN

Chief of the Gastrointestinal Medical Oncology Service in the Division of Solid Tumor Oncology, Department of Medicine at Memorial Sloan Kettering Cancer Center in New York. Dr. Janjigian is an international expert in cancers of the esophagus and stomach.

DR. STEVEN BARKER

Pharmadrug's lead advisor on R&D initiatives for DMT. Dr. Barker is actively involved in the research of psychedelics, with a primary focus on DMT since 1976. Dr Barker also is professor emeritus at Louisiana State University.

DR. JIMO BORJIGIN

Associate Professor in the Department of Molecular and Integrative Physiology and the Department of Neurology at the University of Michigan. Dr. Borjigin received her PhD in Neuroscience from Johns Hopkins University and has been publishing foundational research on DMT since 2012.

TERRY BOOTH

Global cannabis industry pioneer and founder of Aurora Cannabis (TSX- ACB). Mr.Booth brings Significant capital markets and M&A expertise, deep knowledge of the European cannabis markets and is a prominent investor in the psychedelics space.

Capitalization summary

Common Shares	340.1M
Warrants & Options	124.1M
$816,000 Debentures Convertible at $0.05[1]	16.3M
Fully Diluted ITM Shares Outstanding	**480.5M**

Current Cash Position	~$2.5M
Marketable Securities	~$0.9M

All currency amounts in Canadian Dollars

[1] Each debenture is convertible into 1 unit at a conversion price of $0.05. Each unit consists of one common share and one-half of one common share warrant exercisable at $0.07.

Contact information

DANIEL COHEN

Chairman & Chief Executive Officer

77 King Street West, Suite 2905, Toronto,
ON M5K 1H1

dcohen@pharmadrug.co

647-202-1824

pharmadrug.co

PHARMADRUG™